{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Complete Remission (CR)"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Hematological Improvement (HI)"},{"measurements":[{"groupId":"OG000","value":"19"}],"title":"Stable Disease (SD)"},{"measurements":[{"groupId":"OG000","value":"14"}],"title":"Progressive Disease (PD)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Response recorded from the start of the treatment until disease progression/recurrence. All responses must last for at least 8 weeks. Complete Remission (CR): Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines, Persistent dysplasia will be noted, Peripheral blood: Hemoglobin ≥ 11 g/dL, Platelets ≥ 100 x 10\\^9/L, Neutrophils ≥ 1.0 x 10\\^9/L, Blasts 0% ; Partial Remission (PR): All CR criteria if abnormal before treatment, except: Bone marrow blasts decreased by ≥ 50% over pretreatment but still \\> 5%, Cellularity and morphology not relevant; Marrow CR or Hematological Improvement (HI): Bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment Peripheral blood: if HI responses, they will be noted in addition to marrow CR. Further investigation of PF-04449913 would not be warranted if it produced an overall response rate (CR + PR + marrow CR+HI) of 10% or less (p0), and would be warranted if it produced an overall response rate of 30% or more (p1).","groups":[{"description":"Treatment to be administered on an outpatient basis. All participants to be treated with an oral dose PF-04449913 at 100 mg daily in 4-week cycles for a total of 4 cycles.","id":"OG000","title":"Experimental: PF-04449913 Treatment"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants","reportingStatus":"POSTED","timeFrame":"Up to 2 years, 4 months","title":"Overall International Working Group (IWG) 2006 Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}